Cellebrite DI Ltd. (NASDAQ:CLBT) Sees Large Drop in Short Interest

Cellebrite DI Ltd. (NASDAQ:CLBT) saw a large decrease in short interest in January. As of January 30th, there was short interest totaling 4,933,415 shares, a decrease of 17.0% from the January 15th total of 5,947,018 shares. Approximately 2.2% of the company’s stock are sold short. Based on an average daily trading volume, of 1,951,160 shares, the days-to-cover ratio is currently 2.5 days. Based on an average daily trading volume, of 1,951,160 shares, the days-to-cover ratio is currently 2.5 days. Approximately 2.2% of the company’s stock are sold short.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. JPMorgan Chase & Co. lifted their target price on Cellebrite DI from $23.00 to $24.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Wall Street Zen cut Cellebrite DI from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Needham & Company LLC cut their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, February 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellebrite DI in a research note on Monday, December 29th. Finally, Bank of America increased their price objective on shares of Cellebrite DI from $24.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $22.50.

Cellebrite DI Stock Down 2.3%

Shares of NASDAQ CLBT opened at $14.30 on Wednesday. The stock has a market cap of $3.42 billion, a PE ratio of 46.13, a price-to-earnings-growth ratio of 2.15 and a beta of 1.28. Cellebrite DI has a 52-week low of $13.10 and a 52-week high of $20.86. The business has a 50-day moving average price of $16.90 and a 200 day moving average price of $17.03.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings data on Wednesday, February 11th. The company reported $0.14 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.14. The company had revenue of $128.82 million during the quarter, compared to analysts’ expectations of $126.07 million. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The firm’s revenue for the quarter was up 28.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.10 earnings per share. Sell-side analysts anticipate that Cellebrite DI will post 0.3 earnings per share for the current year.

Institutional Investors Weigh In On Cellebrite DI

Hedge funds have recently made changes to their positions in the business. Voss Capital LP increased its position in Cellebrite DI by 18.9% in the 4th quarter. Voss Capital LP now owns 8,050,000 shares of the company’s stock valued at $145,142,000 after acquiring an additional 1,277,300 shares during the period. Pertento Partners LLP increased its holdings in shares of Cellebrite DI by 28.2% in the fourth quarter. Pertento Partners LLP now owns 5,959,324 shares of the company’s stock valued at $107,447,000 after purchasing an additional 1,311,109 shares during the period. Invesco Ltd. raised its stake in shares of Cellebrite DI by 58.6% during the third quarter. Invesco Ltd. now owns 5,560,196 shares of the company’s stock worth $103,030,000 after purchasing an additional 2,054,644 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd raised its stake in shares of Cellebrite DI by 17.1% during the second quarter. Clal Insurance Enterprises Holdings Ltd now owns 3,913,014 shares of the company’s stock worth $62,608,000 after purchasing an additional 570,000 shares during the last quarter. Finally, Granahan Investment Management LLC lifted its holdings in shares of Cellebrite DI by 16.3% during the fourth quarter. Granahan Investment Management LLC now owns 3,057,018 shares of the company’s stock worth $55,118,000 after purchasing an additional 427,719 shares during the period. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.